Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf231 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Rinko Lau und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Anti-Bacterial Agents, Lymphohistiocytosis, Hemophagocytic, Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to review existing literature regarding the association between haemophagocytic lymphohistiocytosis (HLH) and trimethoprim/sulfamethoxazole and examine the risk of HLH using data from the FDA Adverse Event Reporting System (FAERS).
Methods
We conducted a literature review to identify studies investigating the link between trimethoprim/sulfamethoxazole and HLH. Additionally, we performed an active-comparator restricted disproportionality analysis (ACR-DA) in FAERS (2004Q1–2023Q4) for trimethoprim/sulfamethoxazole compared to amoxicillin/clavulanate and azithromycin. We calculated reporting odds ratios (ROR), adjusted ROR (accounting for age category and indications for respiratory and urinary tract infections), proportional reporting ratios and information components (IC25), to identify potential safety signals for HLH.
Results
Our literature review identified five case reports of HLH linked to trimethoprim/sulfamethoxazole, showing a male predominance of 80% and a median age of 39 years. Symptoms appeared 2 to 14 days after initiating treatment, with fever being the first symptom reported in all patients. The disproportionality analysis indicated that reports of HLH associated with trimethoprim/sulfamethoxazole were approximately 3 to 14 times more frequent than those for amoxicillin/clavulanate (ROR, 3.08; 95% CI, 1.67–5.68) and azithromycin (ROR, 13.89; 95% CI, 5.88–32.82), with most reports submitted by other healthcare professionals.
Conclusions
Trimethoprim/sulfamethoxazole may be linked to an increased risk of HLH. Further pharmacoepidemiologic research is necessary to confirm these findings and inform the safe clinical use of trimethoprim/sulfamethoxazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology, Western University, London, ON, Canada.
- Department of Biology, Western University, London, ON, Canada.
- Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
- ICES Western, Kidney Dialysis and Transplantation Research Program, London, ON, Canada.
- Lawson Health Research Institute, London Health Sciences Centre, London, ON, Canada.
ORCID-Profile: Mohammad Ali Omrani, Flory T Muanda
Zitieren
APA
Lau, R., Sadeghi, H., Ahmadi, F., Chalabianloo, N., Preyra, R., Omrani, M. A., & Muanda, F. T. (2025). Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf231
Vancouver
Lau R, Sadeghi H, Ahmadi F, Chalabianloo N, Preyra R, Omrani MA, et al. Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf231
BibTeX
@article{Lau2025,
author = {Lau, Rinko and Sadeghi, Hasti and Ahmadi, Fatemeh and Chalabianloo, Niaz and Preyra, Rebecca and Omrani, Mohammad Ali and Muanda, Flory T},
title = {Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf231}
}
EUVIMED